Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
A great scientific effort has been made to redefine response monitoring, resulting in the development and validation of high-sensitivity techniques to detect minimal residual disease (MRD). MRD is an important factor independently predicting prognosis during MM treatment. Using novel combination therapies, MRD-negative status can be achieved in a high percentage of patients. MRD monitoring can guide treatment intensity, although well-designed clinical trials are needed to demonstrate this potential.